NASDAQ · CRVS
Corvus Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CRVS: Nov 05, 2026
Corvus Pharmaceuticals, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.21. The reported EPS for the same quarter last year was $-0.12.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.21 | $-0.18 | $-0.23 | 2 |
| Dec 2026 | $-0.21 | $-0.18 | $-0.23 | 2 |
| Mar 2027 | $-0.22 | $-0.21 | $-0.23 | 2 |
| Jun 2027 | $-0.23 | $-0.22 | $-0.24 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · The Motley Fool · MarketBeat- BNK Invest · Oct 15, 3:45 PM EDTNoteworthy Thursday Option Activity: NOW, WOLF, CRVSAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ServiceNow Inc (Symbol: NOW), where a total of 96,914 contracts have traded so far, representing approximately 9.7 million underlying shares. That amounts to about 91.6%
- RTTNews · Oct 1, 1:53 AM EDTCorvus Begins Patient Enrollment In Phase 1b Soquelitinib Trial For Hidradenitis Suppurativa(RTTNews) – Wednesday, Corvus Pharmaceuticals, Inc. (CRVS) reported the initiation of Phase 1b clinical trial of Soquelitinib in patients with moderate to severe Hidradenitis suppurativa, with enrollment underway.
- The Motley Fool · Aug 14, 11:42 AM EDTCorvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 6, 8:03 PM EDTCorvus Pharmaceuticals Q2 Earnings Call HighlightsMomentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected milestones across pro
- The Motley Fool · Jun 23, 3:40 PM EDTCorvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?David Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on June 11, 2026.
- The Motley Fool · May 17, 4:46 PM EDTBoxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next PhaseBoxer Capital acquired 1,100,000 shares of Corvus Pharmaceuticals in the first quarter; the estimated trade size was $17.55 million.
- Fintel · Apr 17, 1:34 PM EDTGoldman Sachs Initiates Coverage of Corvus Pharmaceuticals (CRVS) with Buy RecommendationFintel reports that on April 17, 2026, Goldman Sachs initiated coverage of Corvus Pharmaceuticals (NasdaqGM:CRVS) with a Buy recommendation. Analyst Price Forecast Suggests 138.50% Upside
- The Motley Fool · Mar 12, 11:30 PM EDTCorvus (CRVS) Q4 2025 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Feb 3, 6:00 PM ESTCorvus Pharmaceuticals (CRVS) Price Target Increased by 128.26% to 35.70The average one-year price target for Corvus Pharmaceuticals (NasdaqGM:CRVS) has been revised to $35.70 / share. This is an increase of 128.26% from the prior estimate of $15.64 dated January 11, 2026. The price target is an average of many targets provided by
- BNK Invest · Feb 2, 11:46 AM ESTCommit To Buy Corvus Pharmaceuticals At $8, Earn 20% Using OptionsInvestors considering a purchase of Corvus Pharmaceuticals Inc (Symbol: CRVS) stock, but tentative about paying the going market price of $21.47/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract i
- MarketBeat · Feb 2, 10:39 AM ESTMomentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might obscure the fact that a number of individual companies have had a supercharged star
- Zacks · Jan 27, 12:15 PM ESTCorvus Pharmaceuticals Stock Rallies 209% in a Month: Here's WhyCRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Corvus Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.